Obinutuzumab‐induced acute thrombocytopenia: Report of two cases and review of literature
Open Access
- 5 May 2023
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 202 (1) , 168-172
Abstract
Summary: Obinutuzumab (GA101) is a humanized anti‐CD20 monoclonal antibody used in the treatment of B‐cell malignancies. Under rare occasions, obinutuzumab may induce acute and severe thrombocytopenia. However, little is known about this side effect, referred to as “obinutuzumab‐induced acute thrombocytopenia” (OIAT). Here, we report 2 cases of OIAT and review the literature to inform the management and outcome of this rare but life‐threatening complication. The first case is a 74 year‐ old woman who was treated with obinutuzumab‐Cyclophosphamide, Vincristine, Prednisone (CVP) for a previously untreated follicular lymphoma. This patient experienced an acute thrombocytopenia with a drop in her platelet count from 376 G/L to 3 G/L the day after treatment. The second case is a 44 year‐ old woman who was treated with obinutuzumab as a pre‐treatment dose (day‐8) before glofitamab infusion as a 4th line therapy for mantle cell lymphoma. This patient experienced an acute thrombocytopenia with a drop in her platelet count from 76 G/L (due to splenomegaly and bone marrow involvement) to 3 G/L the day after treatment. OIAT is a rare but life‐threatening complication. Physicians should be aware of this adverse event to optimally detect and treat this complication.Keywords
This publication has 12 references indexed in Scilit:
- Drug-induced thrombocytopenia: Focus on platelet apoptosisChemico-Biological Interactions, 2018
- Rituximab-induced Acute Thrombocytopenia in a Patient with Follicular Lymphoma: A Case Report and Review of the LiteratureInternal Medicine, 2018
- Obinutuzumab for the First-Line Treatment of Follicular LymphomaNew England Journal of Medicine, 2017
- Platelet desialylation is a novel mechanism and a therapeutic target in thrombocytopenia during sepsis: an open-label, multicenter, randomized controlled trialJournal of Hematology & Oncology, 2017
- Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trialThe Lancet Oncology, 2016
- Obinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12Blood Cancer Journal, 2016
- Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopeniaNature Communications, 2015
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting ConditionsNew England Journal of Medicine, 2014
- Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and managementJournal of Thrombosis and Haemostasis, 2009
- Drug-Induced Immune ThrombocytopeniaNew England Journal of Medicine, 2007